XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.3

Collaboration and License Agreements (Details) - USD ($) $ in Thousands				1 Months Ended		3 Months Ended			9 Months Ended
	Nov. 07, 2022	Sep. 14, 2018	Sep. 14, 2018	May 31, 2024	Jun. 30, 2022	Sep. 30, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2025	Dec. 31, 2024	Aug. 31, 2024	Nov. 30, 2023	Dec. 31, 2021	Dec. 31, 2020
Collaboration agreement
Revenue recognized						$ 1,741	$ 3,074		$ 5,277	$ 11,771
Proceeds from issuance of private placement								$ 19,996
Income expense in change in fair value of the stock price appreciation milestones						2,485	4,699		9,042	14,419
Candidate 2
Collaboration agreement
Clinical development milestone fees				$ 5,000
Ono Pharmaceutical Company Ltd
Collaboration agreement
Non-refundable upfront payments recorded as deferred revenue			$ 10,000
Non-refundable upfront payments recorded as deferred revenue		$ 10,000	10,000
Aggregate research and development fees payments receivable		20,000	20,000
Collaborative arrangement potential additional milestones		44,500	$ 44,500
Transaction price of the agreement		54,500
Revenue recognized						1,700	3,100		5,300	11,800
Ono Pharmaceutical Company Ltd | Candidate 1
Collaboration agreement
Percentage of reduction on milestone payments			50.00%
Ono Pharmaceutical Company Ltd | Candidate 2
Collaboration agreement
Milestone payments		10,000	$ 10,000
Milestone payment under Deferred revenue		10,000
Collaborative arrangement annual payments receivable recorded as deferred revenue		$ 5,000
Contra research and development expenses						1,300	1,700		4,500	3,600
Option exercise payment	$ 12,500
Ono Pharmaceutical Company Ltd | Minimum | Candidate 1
Collaboration agreement
Profits and losses sharing percentage					50.00%
Collaborative arrangement potential additional milestones					$ 9,300									$ 1,400
Ono Pharmaceutical Company Ltd | Minimum | Candidate 3
Collaboration agreement
Collaborative arrangement potential additional milestones											$ 6,500		$ 7,300
Ono Pharmaceutical Company Ltd | Maximum | Candidate 1
Collaboration agreement
Collaborative arrangement potential additional milestones					$ 29,300									$ 30,700
Ono Pharmaceutical Company Ltd | Maximum | Candidate 2
Collaboration agreement
Aggregate milestone payments			$ 843,000
Ono Pharmaceutical Company Ltd | Maximum | Candidate 3
Collaboration agreement
Collaborative arrangement potential additional milestones											$ 44,500		$ 38,000
Amended Mskcc License
Collaboration agreement
Enterprise value milestone payment						75,000			75,000
Stock price appreciation milestone payable															$ 20,000
Enterprise value milestones liability at fair value						400			400			$ 500
Amended MSK License
Collaboration agreement
Income expense in change in fair value of the stock price appreciation milestones						$ 100	$ 100		$ 100	$ 100
Ono Letter Agreement | Ono Pharmaceutical Company Ltd
Collaboration agreement
Milestone payments																$ 10,000

X

- Definition

Clinical Development Milestone Fees

+ References

No definition available.

+ Details

Name:	fate_ClinicalDevelopmentMilestoneFees
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaborative arrangement aggregate milestone payments receivable.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangement aggregate payments receivable.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAggregatePaymentsReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Collaborative arrangement annual payments receivable recorded under deferred revenue.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaborative arrangement percentage of reduction on milestone payments.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments
Namespace Prefix:	fate_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangement potential additional milestones.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementPotentialAdditionalMilestones
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue.

+ References

No definition available.

+ Details

Name:	fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Contra research and development expenses

+ References

No definition available.

+ Details

Name:	fate_ContraResearchAndDevelopmentExpenses
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Enterprise value milestone payment.

+ References

No definition available.

+ Details

Name:	fate_EnterpriseValueMilestonePayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Enterprise Value Milestones Liability At Fair Value.

+ References

No definition available.

+ Details

Name:	fate_EnterpriseValueMilestonesLiabilityAtFairValue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone Payment Under Deferred Revenue

+ References

No definition available.

+ Details

Name:	fate_MilestonePaymentUnderDeferredRevenue
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone payments during the period.

+ References

No definition available.

+ Details

Name:	fate_MilestonePayments
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Option exercise payment.

+ References

No definition available.

+ Details

Name:	fate_OptionExercisePayment
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Profit loss sharing percentage.

+ References

No definition available.

+ Details

Name:	fate_ProfitLossSharingPercentage
Namespace Prefix:	fate_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Stock price appreciation milestone payable.

+ References

No definition available.

+ Details

Name:	fate_StockPriceAppreciationMilestonePayable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Transaction price of agreement.

+ References

No definition available.

+ Details

Name:	fate_TransactionPriceOfAgreement
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront non-refundable non-creditable payment receivable.

+ References

No definition available.

+ Details

Name:	fate_UpfrontNonRefundableNonCreditablePaymentReceivable
Namespace Prefix:	fate_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_TitleOfIndividualAxis=fate_CandidateThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=fate_OnoLetterAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: